Evaluation of Systemic Inflammation Based Prognostic Scores in Patients with Advanced Oesophageal Cancer Receiving Palliative Radiotherapy

Dolan, R. , Tilling, E., Kong, C. Y., MacLeod, N. J., McSorley, S. T. , Park, J. H. , Glen, P., Horgan, P. G. , Laird, B. and McMillan, D. C. (2018) Evaluation of Systemic Inflammation Based Prognostic Scores in Patients with Advanced Oesophageal Cancer Receiving Palliative Radiotherapy. Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 18-20 Jan 2018.

Full text not currently available from Enlighten.

Abstract

Background: The presence of a systemic inflammatory response (SIR) in patients with advanced cancer is an increasingly recognised prognostic domain and is commonly assessed by the Glasgow Prognostic Score (GPS) and modified Glasgow Prognostic Score (mGPS). However, little work has been carried out to evaluate their role in palliative radiotherapy. The aim of the present study was to compare the prognostic value of the GPS/mGPS in patients with advanced oesophageal cancer receiving palliative radiotherapy. Methods: Those patients receiving palliative radiotherapy for oesophageal cancer between 2010 and 2015 were examined (n=194). After exclusions the following demographic data was recorded sex, age, indication for radiotherapy, time from treatment to death/last clinic visit, medical comorbidities, tumour and radiotherapy location/dose, CRP, albumin, and differential blood counts. GPS, mGPS, NLR, PLR and LMR were all calculated and Cox regression analysis carried out in SPSS. Results: Patients who had undergone non-oesophageal/neoadjuvant radiotherapy (n=2) or died within 30 days of treatment administration were excluded (n=22). Of the remaining 170 analysed, 112 (66%) were male and the median age was 72 (Range: 43-91). The most common clinical indications for radiotherapy were dysphagia (n=142), weight loss (n=81) and pain (n=50). Medical comorbidities varied with the most common being hypertension (n=83), ischaemic heart disease (n=46) and COPD (n=42). At the time of analysis, 170 (100%) of the patients were dead with median survival of 6 months (Range: 1-81 month). On univariate six month cancer specific survival analysis, TNM stage (p=0.028), GPS (p<0.001) and mGPS (p<0.001) were significantly associated with poor survival. On multivariate analysis of the significant variables, only mGPS (HR: 2.28, 95%CI 1.29-4.01, p=0.004) and TNM stage (HR: 1.71 95%CI 1.09-2.69, p=0.020) remained independently associated with survival. Conclusions: In the palliative radiotherapy setting, systemic inflammation based scores (GPS/mGPS) had prognostic value and the mGPS had independent prognostic value.

Item Type:Conference or Workshop Item
Additional Information:Abstract published in Journal of Clinical Oncology 36(S4):21, http://dx.doi.org/10.1200/JCO.2018.36.4_suppl.21
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Park, Mr James and Horgan, Professor Paul and McSorley, Dr Stephen and Dolan, Dr Ross and Glen, Mr Paul and McMillan, Professor Donald and Kong, Dr Chia Yew and Laird, Dr Barry
Authors: Dolan, R., Tilling, E., Kong, C. Y., MacLeod, N. J., McSorley, S. T., Park, J. H., Glen, P., Horgan, P. G., Laird, B., and McMillan, D. C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing

University Staff: Request a correction | Enlighten Editors: Update this record